









Markets
/
Stocks
/
nasdaq-gh
/

Guardant Health Inc

88.100USD

+1.520+1.76%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

7.36BMarket Cap

LossP/E TTM



Guardant Health Inc

88.100

+1.520+1.76%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Guardant Health Inc

Currency: USD Updated: 2026-03-26

Key Insights

Guardant Health Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 45 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 129.67.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Guardant Health Inc's Score

Industry at a Glance

Industry Ranking

45 / 209

Overall Ranking

132 / 4546

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Guardant Health Inc Highlights

StrengthsRisks

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 74.13% year-on-year.

Undervalued

The company’s latest PE is -26.53, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 125.59M shares, decreasing 11.76% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 9.94K shares of this stock.

Analyst Rating

Based on 26 analysts

Buy

Current Rating

129.671

Target Price

+55.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of Guardant Health Inc is 6.26, ranking 158 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 281.27M, representing a year-over-year increase of 39.37%, while its net profit experienced a year-over-year increase of 15.75%.

Score

Industry at a Glance

Previous score

6.26

Change



Financials

5.10

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.55

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.38

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.16

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Guardant Health Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of Guardant Health Inc is 7.26, ranking 102 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -26.53, which is -100.00% below the recent high of 0.00 and -37.57% above the recent low of -36.50.

Score

Industry at a Glance

Previous score

7.26

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 45/209

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of Guardant Health Inc is 8.62, ranking 19 out of 209 in the Healthcare Equipment & Supplies industry. The average price target is 100.00, with a high of 130.00 and a low of 48.21.

Score

Industry at a Glance

Previous score

8.62

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 26 analysts

Buy

Current Rating

129.671

Target Price

+55.13%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

Guardant Health Inc

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of Guardant Health Inc is 7.36, ranking 37 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 95.97 and the support level at 81.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.05

Change

0.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.892

Neutral

RSI(14)

43.260

Neutral

STOCH(KDJ)(9,3,3)

56.175

Buy

ATR(14)

3.929

High Vlolatility

CCI(14)

9.315

Neutral

Williams %R

44.142

Buy

TRIX(12,20)

-0.688

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

85.682

Buy

MA10

86.618

Buy

MA20

88.808

Sell

MA50

100.041

Sell

MA100

101.043

Sell

MA200

78.827

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Guardant Health Inc is 10.00, ranking 1 out of 209 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 97.48%, representing a quarter-over-quarter decrease of 2.59%. The largest institutional shareholder is The Vanguard, holding a total of 12.13M shares, representing 9.25% of shares outstanding, with 4.92% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

11.88M

-2.14%

BlackRock Institutional Trust Company, N.A.

8.57M

+2.09%

T. Rowe Price Associates, Inc.

Star Investors

4.10M

+148.51%

Invesco Advisers, Inc.

4.64M

+36.43%

Baillie Gifford & Co.

Star Investors

5.13M

+6.61%

Two Sigma Investments, LP

3.92M

-7.56%

Capital International Investors

4.69M

-5.77%

Geode Capital Management, L.L.C.

2.94M

+0.55%

Franklin Advisers, Inc.

2.91M

+25.80%

Deep Track Capital LP

4.15M

-2.26%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Guardant Health Inc is 5.67, ranking 76 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.69. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.